Case study: How trial design simulation supports successful funding rounds

As life-threatening and difficult-to-treat conditions continue to impact vulnerable populations, the urgency for effective therapies is growing.

Explore how MMS provided expert biostatistics and its advanced KerusCloud simulation platform to transform RSV trial design.

Read now and learn how:

KerusCloud simulation used real patient-level data, literature and results from past completed studies in RSV
Biostatistics and simulation optimized trial study design
Risk, cost and timelines were dramatically reduced
Evidence generated helped secure US$30 million in a subsequent financing round

Download the case study

Your Company Email Address

Opt In?

By completing this form you agree Citeline and MMS may store and process your personal data as well as contact you directly about industry news, products, services and events that may be of interest to you subject to the privacy policies of Citeline and MMS.